uniQure Reports Second Dose Cohort Demonstrated 89% Reduction in Spontaneous Bleeds, with No Confirmed Bleeds Reported in Last 12 Mo.; Clinical Benefit Maintained in All Patients, with Durable Increases in FIX Clotting Activity At Up To 2 Years Follow Up